Below are the most recent publications written about "Off-Label Use" by people in Profiles.
-
Wiecek W, Ahuja A, Chaudhuri E, Kremer M, Simoes Gomes A, Snyder CM, Tabarrok A, Tan BJ. Testing fractional doses of COVID-19 vaccines. Proc Natl Acad Sci U S A. 2022 02 22; 119(8).
-
Gopal AD, Wallach JD, Shah SA, Regillo C, Ross JS. On-Label and Off-Label Clinical Studies of FDA-Approved Ophthalmic Therapeutics. Ophthalmology. 2021 02; 128(2):332-334.
-
Sedhom R, Abdelmaseeh P, Megaly M, Asinger R. Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombi: A Systematic Review. Am J Med. 2020 11; 133(11):1266-1273.e6.
-
Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, Muyembe TamFum JJ, Seydi M, Eholie SP, Mills EJ, Kallay O, Zumla A, Nachega JB. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. Am J Trop Med Hyg. 2020 06; 102(6):1184-1188.
-
Igelman S, Kurta AO, Sheikh U, McWilliams A, Armbrecht E, Jackson Cullison SR, Kress DW, Smith A, Castelo-Soccio L, Treat J, Boothe WD, Diaz LZ, Levy ML, Patel A, Lee LW, Fraile-Alonso MC, Antaya RJ, Shah S, Kittler N, Arkin L, Siegfried E. Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review. J Am Acad Dermatol. 2020 Feb; 82(2):407-411.
-
Garg S, McCarthy JJ, Goodwin R, Kolmodin J, Sankar WN, Franklin C, Armstrong D, Fryzel D, Hassenbein S, Meder C. Complication Rates After Bone Morphogenetic Protein (BMP) Use in Orthopaedic Surgery in Children: A Concise Multicenter Retrospective Cohort Study. J Pediatr Orthop. 2017 Sep; 37(6):e375-e378.
-
LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017 Mar; 13(3):181-188.
-
Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol. 2016 Dec 20; 68(24):2597-2604.
-
Sobel RM, Wu DT, Hester K, Anda K. Tissue plasminogen activator for transient ischemic attack: the case for "off-label" use of thrombolytics. Am J Emerg Med. 2014 Mar; 32(3):277-9.
-
Carragee EJ, Baker RM, Benzel EC, Bigos SJ, Cheng I, Corbin TP, Deyo RA, Hurwitz EL, Jarvik JG, Kang JD, Lurie JD, Mroz TE, Oner FC, Peul WC, Rainville J, Ratliff JK, Rihn JA, Rothman DJ, Schoene ML, Spengler DM, Weiner BK. A biologic without guidelines: the YODA project and the future of bone morphogenetic protein-2 research. Spine J. 2012 Oct; 12(10):877-80.